Principal Leads and Breaking News in T21 Research
Principal Leads in Research
The GABA Transmission Several teams from San Diego and Stanford (USA) have demonstrated the existence of impaired nerve transmission in the brain of mouse models of Down Syndrome, the Ts65Dn. These teams have shown that inhibition of GABA’s receptors leads to the virtual disappearance of these disorders, particularly those of memory. However, the family of Click to Continue Reading…
The DYRK1A Program When it works too hard, the chromosome 21′s DYRK1A gene is causing morphological and cognitive impairments on Down Syndrome’s Mice models (Ts65Dn mice). It is likely that the hyper function of this gene has the same effect on humans affected by Down Syndrome. The DYRK1A gene encodes for an enzyme (also called Click to Continue Reading…
The research program CiBleS21, was initiated by the Jérôme Lejeune Foundation in 2004, to investigate the relationship of the CBS gene to the intellectual impairment associated with trisomy 21, and to also research treatments intended to address the intellectual disabilitiy. Chromosome 21 is the smallest of the human chromosomes containing some 570 genes. One of Click to Continue Reading…
Breaking News in Research
Choline improves, in a mouse model of trisomy 21, the symptoms of trisomy 21
A study published June 2, 2010 in Behavioral Neuroscience demonstrated in mice whose mothers were supplemented with choline during pregnancy and while breastfeeding, improved “emotional control and mental capacities.” Choline is an intermediate molecule of the amino alcohol family. Preliminary results, still to be confirmed.
6 new Cystathionine Beta Synthase’s inhibitors have been discovered
The Jerome Lejeune Foundation research department announce the discovery of 6 new cystathionine beta synthesis’ inhibitors, an enzyme that constitutes a major target in the research of a treatment against Down Syndrome. It is a very important step that has to be confirmed by further studies.
QR Pharma register a patent on Posiphen’s usage for the treatment of Down Syndrome
The Phosiphen has proved its capacity to reduce the APP synthesis on mice. Explanation: Down syndrome affected mice treated with Posiphen have shown that some brain areas which would normally have degenerated are preserved.
